-
1
-
-
79958237659
-
Modelling the costs of care of hypertension in patients with metabolic syndrome and its consequences, in Germany, Spain and Italy
-
Apr 20 Epub ahead of print. DOI 10.1007/s10198-010-0223-9
-
Wille E, Scholze J, Alegria E, et al: Modelling the costs of care of hypertension in patients with metabolic syndrome and its consequences, in Germany, Spain and Italy. Eur J Health Econ Apr 20 2010. [Epub ahead of print.] DOI 10.1007/s10198-010-0223-9.
-
(2010)
Eur J Health Econ
-
-
Wille, E.1
Scholze, J.2
Alegria, E.3
-
2
-
-
0037463608
-
The metabolic syndrome: Prevalence and associated risk factor findings in the US population from the Third National Health and Nutrition Examination Survey, 1988-1994
-
Park YW, Zhu S, Palaniappan L, et al: The metabolic syndrome: Prevalence and associated risk factor findings in the US population from the Third National Health and Nutrition Examination Survey, 1988-1994. Arch Intern Med 163:427-436, 2003.
-
(2003)
Arch Intern Med
, vol.163
, pp. 427-436
-
-
Park, Y.W.1
Zhu, S.2
Palaniappan, L.3
-
3
-
-
0037116641
-
Prevalence of the metabolic syndrome among US adults: Findings from the Third National Health and Nutrition Examination Survey
-
Ford ES, Giles WH, Dietz WH: Prevalence of the metabolic syndrome among US adults: Findings from the Third National Health and Nutrition Examination Survey. JAMA 287:356-359, 2002. (Pubitemid 34251969)
-
(2002)
Journal of the American Medical Association
, vol.287
, Issue.3
, pp. 356-359
-
-
Ford, E.S.1
Giles, W.H.2
Dietz, W.H.3
-
5
-
-
58149265222
-
Long-term rates of cardiovascular events in patients with the metabolic syndrome according to severity of coronary-angiographic alterations
-
Solymoss BC, Bourassa MG, Marcil M, et al: Long-term rates of cardiovascular events in patients with the metabolic syndrome according to severity of coronary-angiographic alterations. Coron Artery Dis 20:1-8, 2009.
-
(2009)
Coron Artery Dis
, vol.20
, pp. 1-8
-
-
Solymoss, B.C.1
Bourassa, M.G.2
Marcil, M.3
-
6
-
-
54049091645
-
Nonalcoholic fatty liver disease: Hepatic manifestation of obesity and the metabolic syndrome
-
Boppidi H, Daram SR: Nonalcoholic fatty liver disease: Hepatic manifestation of obesity and the metabolic syndrome. Postgrad Med 120:E01-E07, 2008.
-
(2008)
Postgrad Med
, vol.120
-
-
Boppidi, H.1
Daram, S.R.2
-
8
-
-
33749058933
-
Diabetes and cardiovascular disease during androgen deprivation therapy for prostate cancer
-
Keating NL, OMalley AJ, Smith MR: Diabetes and cardiovascular disease during androgen deprivation therapy for prostate cancer. J Clin Oncol 24:4448-4456, 2006.
-
(2006)
J Clin Oncol
, vol.24
, pp. 4448-4456
-
-
Keating, N.L.1
OMalley, A.J.2
Smith, M.R.3
-
9
-
-
38049095554
-
Do adjuvant aromatase inhibitors increase the cardiovascular risk in postmenopausal women with early breast cancer? Meta-analysis of randomized trials
-
Cuppone F, Bria E, Verma S, et al: Do adjuvant aromatase inhibitors increase the cardiovascular risk in postmenopausal women with early breast cancer? Meta-analysis of randomized trials. Cancer 112:260-267, 2008.
-
(2008)
Cancer
, vol.112
, pp. 260-267
-
-
Cuppone, F.1
Bria, E.2
Verma, S.3
-
10
-
-
0015107440
-
Metabolic studies in a patient with testicular feminization syndrome
-
Castaneda E, Perez AE, Guillen MA, et al: Metabolic studies in a patient with testicular feminization syndrome. Am J Obstet Gynecol 110:1002-1007, 1971.
-
(1971)
Am J Obstet Gynecol
, vol.110
, pp. 1002-1007
-
-
Castaneda, E.1
Perez, A.E.2
Guillen, M.A.3
-
11
-
-
0019943749
-
Abnormalities of fuel metabolism in the polycystic ovary syndrome
-
Wortsman J, Soler NG: Abnormalities of fuel metabolism in the polycystic ovary syndrome. Obstet Gynecol 60:342-345, 1982.
-
(1982)
Obstet Gynecol
, vol.60
, pp. 342-345
-
-
Wortsman, J.1
Soler, N.G.2
-
12
-
-
43149087991
-
Body mass index and ovarian function are associated with endocrine and metabolic abnormalities in women with hyperandrogenic syndrome
-
DOI 10.1530/EJE-07-0515
-
Cupisti S, Kajaia N, Dittrich R, et al: Body mass index and ovarian function are associated with endocrine and metabolic abnormalities in women with hyperandrogenic syndrome. Eur J Endocrinol 158:711-719, 2008. (Pubitemid 351639610)
-
(2008)
European Journal of Endocrinology
, vol.158
, Issue.5
, pp. 711-719
-
-
Cupisti, S.1
Kajaia, N.2
Dittrich, R.3
Duezenli, H.4
Beckmann, M.W.5
Mueller, A.6
-
13
-
-
33644674139
-
Gender differences in the metabolic syndrome and their role for cardiovascular disease
-
Regitz-Zagrosek V, Lehmkuhl E, Weickert MO: Gender differences in the metabolic syndrome and their role for cardiovascular disease. Clin Res Cardiol 95:136-147, 2006.
-
(2006)
Clin Res Cardiol
, vol.95
, pp. 136-147
-
-
Regitz-Zagrosek, V.1
Lehmkuhl, E.2
Weickert, M.O.3
-
14
-
-
35048904131
-
Duration of testosterone suppression and the risk of death from prostate cancer in men treated using radiation and 6 months of hormone therapy
-
DAmico AV, Renshaw AA, Loffredo B, Chen MH: Duration of testosterone suppression and the risk of death from prostate cancer in men treated using radiation and 6 months of hormone therapy. Cancer 110:1723-1728, 2007.
-
(2007)
Cancer
, vol.110
, pp. 1723-1728
-
-
DAmico, A.V.1
Renshaw, A.A.2
Loffredo, B.3
Chen, M.H.4
-
15
-
-
27744507677
-
Short-term androgen deprivation and radiotherapy for locally advanced prostate cancer: Results from the Trans-Tasman Radiation Oncology Group 96.01 randomised controlled trial
-
Denham JW, Steigler A, Lamb DS, et al: Short-term androgen deprivation and radiotherapy for locally advanced prostate cancer: Results from the Trans-Tasman Radiation Oncology Group 96.01 randomised controlled trial. Lancet Oncol 6:841-850, 2005.
-
(2005)
Lancet Oncol
, vol.6
, pp. 841-850
-
-
Denham, J.W.1
Steigler, A.2
Lamb, D.S.3
-
16
-
-
35548937873
-
Androgen deprivation therapy for localized prostate cancer and the risk of cardiovascular mortality
-
DOI 10.1093/jnci/djm168
-
Tsai HK, DAmico AV, Sadetsky N, et al: Androgen deprivation therapy for localized prostate cancer and the risk of cardiovascular mortality. J Natl Cancer Inst 99:1516-1524, 2007. (Pubitemid 351767235)
-
(2007)
Journal of the National Cancer Institute
, vol.99
, Issue.20
, pp. 1516-1524
-
-
Tsai, H.K.1
D'Amico, A.V.2
Sadetsky, N.3
Chen, M.-H.4
Carroll, P.R.5
-
17
-
-
34648828214
-
Androgen deprivation therapy increases cardiovascular morbidity in men with prostate cancer
-
Saigal CS, Gore JL, Krupski TL, et al: Androgen deprivation therapy increases cardiovascular morbidity in men with prostate cancer. Cancer 110:1493-1500, 2007.
-
(2007)
Cancer
, vol.110
, pp. 1493-1500
-
-
Saigal, C.S.1
Gore, J.L.2
Krupski, T.L.3
-
18
-
-
33748474608
-
Metabolic syndrome in men with prostate cancer undergoing long-term androgen-deprivation therapy
-
DOI 10.1200/JCO.2006.05.9741
-
Braga-Basaria M, Dobs AS, Muller DC, et al: Metabolic syndrome in men with prostate cancer undergoing long-term androgen-deprivation therapy. J Clin Oncol 24:3979-3983, 2006. (Pubitemid 46630747)
-
(2006)
Journal of Clinical Oncology
, vol.24
, Issue.24
, pp. 3979-3983
-
-
Braga-Basaria, M.1
Dobs, A.S.2
Muller, D.C.3
Carducci, M.A.4
John, M.5
Egan, J.6
Basaria, S.7
-
19
-
-
68149138117
-
The dark side of testosterone deficiency: III. Cardiovascular disease
-
Traish AM, Saad F, Feeley RJ, Guay AT: The dark side of testosterone deficiency: III. Cardiovascular disease. J Androl 30:477-494, 2009.
-
(2009)
J Androl
, vol.30
, pp. 477-494
-
-
Traish, A.M.1
Saad, F.2
Feeley, R.J.3
Guay, A.T.4
-
20
-
-
37349025015
-
Association between androgen-deprivation therapy and incidence of diabetes among males with prostate cancer
-
Lage MJ, Barber BL, Markus RA: Association between androgen-deprivation therapy and incidence of diabetes among males with prostate cancer. Urology 70:1104-1108, 2007.
-
(2007)
Urology
, vol.70
, pp. 1104-1108
-
-
Lage, M.J.1
Barber, B.L.2
Markus, R.A.3
-
21
-
-
31544440178
-
Hyperglycemia and insulin resistance in men with prostate carcinoma who receive androgen-deprivation therapy
-
Basaria S, Muller DC, Carducci MA, et al: Hyperglycemia and insulin resistance in men with prostate carcinoma who receive androgen-deprivation therapy. Cancer 106:581-588, 2006.
-
(2006)
Cancer
, vol.106
, pp. 581-588
-
-
Basaria, S.1
Muller, D.C.2
Carducci, M.A.3
-
22
-
-
58149310816
-
The dark side of testosterone deficiency: II. Type 2 diabetes and insulin resistance
-
Traish AM, Saad F, Guay A: The dark side of testosterone deficiency: II. Type 2 diabetes and insulin resistance. J Androl 30:23-32, 2009.
-
(2009)
J Androl
, vol.30
, pp. 23-32
-
-
Traish, A.M.1
Saad, F.2
Guay, A.3
-
23
-
-
39549097295
-
Adipocytokines, Obesity, and Insulin Resistance during Combined Androgen Blockade for Prostate Cancer
-
DOI 10.1016/j.urology.2007.08.035, PII S0090429507020353
-
Smith MR, Lee H, Fallon MA, Nathan DM: Adipocytokines, obesity, and insulin resistance during combined androgen blockade for prostate cancer. Urology 71:318-322, 2008. (Pubitemid 351282338)
-
(2008)
Urology
, vol.71
, Issue.2
, pp. 318-322
-
-
Smith, M.R.1
Lee, H.2
Fallon, M.A.3
Nathan, D.M.4
-
24
-
-
35148842094
-
Risk of new-onset diabetes mellitus and worsening glycaemic variables for established diabetes in men undergoing androgen-deprivation therapy for prostate cancer
-
Derweesh IH, Diblasio CJ, Kincade MC, et al: Risk of new-onset diabetes mellitus and worsening glycaemic variables for established diabetes in men undergoing androgen-deprivation therapy for prostate cancer. BJU Int 100:1060-1065, 2007.
-
(2007)
BJU Int
, vol.100
, pp. 1060-1065
-
-
Derweesh, I.H.1
Diblasio, C.J.2
Kincade, M.C.3
-
26
-
-
0025931791
-
Effects of tamoxifen on cardiovascular risk factors in postmenopausal women
-
Love RR, Wiebe DA, Newcomb PA, et al: Effects of tamoxifen on cardiovascular risk factors in postmenopausal women. Ann Intern Med 115:860-864, 1991.
-
(1991)
Ann Intern Med
, vol.115
, pp. 860-864
-
-
Love, R.R.1
Wiebe, D.A.2
Newcomb, P.A.3
-
27
-
-
0026764412
-
Long term effects of tamoxifen on blood lipid values in breast cancer
-
Dewar JA, Horobin JM, Preece PE, et al: Long term effects of tamoxifen on blood lipid values in breast cancer. BMJ 305:225-226, 1992.
-
(1992)
BMJ
, vol.305
, pp. 225-226
-
-
Dewar, J.A.1
Horobin, J.M.2
Preece, P.E.3
-
28
-
-
0029848389
-
Effects of chemotherapy-induced castration on serum lipids and apoproteins in premenopausal women with node-positive breast cancer
-
DOI 10.1210/jc.81.12.4453
-
Saarto T, Blomqvist C, Ehnholm C, et al: Effects of chemotherapy-induced castration on serum lipids and apoproteins in premenopausal women with node-positive breast cancer. J Clin Endocrinol Metab 81:4453-4457, 1996. (Pubitemid 26412060)
-
(1996)
Journal of Clinical Endocrinology and Metabolism
, vol.81
, Issue.12
, pp. 4453-4457
-
-
Saarto, T.1
Blomqvist, C.2
Ehnholm, C.3
Taskinen, M.-R.4
Elomaa, I.5
-
29
-
-
0029096747
-
Cardiac and vascular morbidity in women receiving adjuvant tamoxifen for breast cancer in a randomised trial. The Scottish Cancer Trials Breast Group
-
McDonald CC, Alexander FE, Whyte BW, et al: Cardiac and vascular morbidity in women receiving adjuvant tamoxifen for breast cancer in a randomised trial. The Scottish Cancer Trials Breast Group. BMJ 311:977-980, 1995.
-
(1995)
BMJ
, vol.311
, pp. 977-980
-
-
McDonald, C.C.1
Alexander, F.E.2
Whyte, B.W.3
-
30
-
-
19344364880
-
Effects of chemotherapy and hormonal therapy for early breast cancer on recurrence and 15-year survival: An overview of the randomised trials
-
Early Breast Cancer Trialists Collaborative Group (EBCTCG)
-
Early Breast Cancer Trialists Collaborative Group (EBCTCG): Effects of chemotherapy and hormonal therapy for early breast cancer on recurrence and 15-year survival: An overview of the randomised trials. Lancet 365:1687-1717, 2005.
-
(2005)
Lancet
, vol.365
, pp. 1687-1717
-
-
-
31
-
-
33746408229
-
Comprehensive side-effect profile of anastrozole and tamoxifen as adjuvant treatment for early-stage breast cancer: Long-term safety analysis of the ATAC trial
-
Arimidex, Tamoxifen, Alone or in Combination Trialists Group
-
Arimidex, Tamoxifen, Alone or in Combination Trialists Group, Buzdar A, Howell A, et al: Comprehensive side-effect profile of anastrozole and tamoxifen as adjuvant treatment for early-stage breast cancer: Long-term safety analysis of the ATAC trial. Lancet Oncol 7:633-643, 2006.
-
(2006)
Lancet Oncol
, vol.7
, pp. 633-643
-
-
Buzdar, A.1
Howell, A.2
-
32
-
-
33947510501
-
Five years of letrozole compared with tamoxifen as initial adjuvant therapy for postmenopausal women with endocrine-responsive early breast cancer: Update of study BIG 1-98
-
DOI 10.1200/JCO.2006.08.8617
-
Coates AS, Keshaviah A, Thurlimann B, et al: Five years of letrozole compared with tamoxifen as initial adjuvant therapy for postmenopausal women with endocrine-responsive early breast cancer: Update of study BIG 1-98. J Clin Oncol 25:486-492, 2007. (Pubitemid 350002953)
-
(2007)
Journal of Clinical Oncology
, vol.25
, Issue.5
, pp. 486-492
-
-
Coates, A.S.1
Keshaviah, A.2
Thurlimann, B.3
Mouridsen, H.4
Mauriac, L.5
Forbes, J.F.6
Paridaens, R.7
Castiglione-Gertsch, M.8
Gelber, R.D.9
Colleoni, M.10
Lang, I.11
Del Mastro, L.12
Smith, I.13
Chirgwin, J.14
Nogaret, J.-M.15
Pienkowski, T.16
Wardley, A.17
Jakobsen, E.H.18
Price, K.N.19
Goldhirsch, A.20
more..
-
33
-
-
37649008623
-
Cardiovascular adverse events during adjuvant endocrine therapy for early breast cancer using letrozole or tamoxifen: Safety analysis of BIG 1-98 trial
-
Mouridsen H, Keshaviah A, Coates AS, et al: Cardiovascular adverse events during adjuvant endocrine therapy for early breast cancer using letrozole or tamoxifen: Safety analysis of BIG 1-98 trial. J Clin Oncol 25:5715-5722, 2007.
-
(2007)
J Clin Oncol
, vol.25
, pp. 5715-5722
-
-
Mouridsen, H.1
Keshaviah, A.2
Coates, A.S.3
-
34
-
-
29544433211
-
A comparison of letrozole and tamoxifen in postmenopausal women with early breast cancer
-
Thurlimann B, Keshaviah A, Coates AS, et al: A comparison of letrozole and tamoxifen in postmenopausal women with early breast cancer. N Engl J Med 353:2747-2757, 2005.
-
(2005)
N Engl J Med
, vol.353
, pp. 2747-2757
-
-
Thurlimann, B.1
Keshaviah, A.2
Coates, A.S.3
-
35
-
-
33749121807
-
Ezetimibe: Effective and safe treatment for dyslipidaemia associated with nonalcoholic fatty liver disease
-
Response to: Toth PP, Davidson MH: Simvastatin and ezetimibe: Combination therapy for the management of dyslipidaemia. Expert Opin Pharmacother 6:131-139, 2005
-
Ahmed MH, Saad RA, Osman MM: Ezetimibe: Effective and safe treatment for dyslipidaemia associated with nonalcoholic fatty liver disease. Response to: Toth PP, Davidson MH: Simvastatin and ezetimibe: Combination therapy for the management of dyslipidaemia. Expert Opin Pharmacother 6:131-139, 2005. Expert Opin Drug Saf 5:487-488, 2006.
-
(2006)
Expert Opin Drug Saf
, vol.5
, pp. 487-488
-
-
Ahmed, M.H.1
Saad, R.A.2
Osman, M.M.3
-
36
-
-
0035131855
-
Relationships between tamoxifen use, liver fat and body fat distribution in women with breast cancer
-
DOI 10.1038/sj.ijo.0801488
-
Nguyen MC, Stewart RB, Banerji MA, et al: Relationships between tamoxifen use, liver fat and body fat distribution in women with breast cancer. Int J Obes Relat Metab Disord 25:296-298, 2001. (Pubitemid 33593532)
-
(2001)
International Journal of Obesity
, vol.25
, Issue.SUPPL. 2
, pp. 296-298
-
-
Nguyen, M.C.1
Stewart, R.B.2
Banerji, M.A.3
Gordon, D.H.4
Kral, J.G.5
-
37
-
-
20244370881
-
Incidence and risk factors for non-alcoholic steatohepatitis: Prospective study of 5408 women enrolled in Italian tamoxifen chemoprevention trial
-
Bruno S, Maisonneuve P, Castellana P, et al: Incidence and risk factors for non-alcoholic steatohepatitis: Prospective study of 5408 women enrolled in Italian tamoxifen chemoprevention trial. BMJ 330:932, 2005.
-
(2005)
BMJ
, vol.330
, pp. 932
-
-
Bruno, S.1
Maisonneuve, P.2
Castellana, P.3
-
38
-
-
44649178193
-
Bilateral oophorectomy before 50 years of age is significantly associated with the metabolic syndrome and Framingham risk score: A controlled, population-based study (HUNT-2)
-
Dørum A, Tonstad S, Liavaag AH, et al: Bilateral oophorectomy before 50 years of age is significantly associated with the metabolic syndrome and Framingham risk score: A controlled, population-based study (HUNT-2). Gynecol Oncol 109:377-383, 2008.
-
(2008)
Gynecol Oncol
, vol.109
, pp. 377-383
-
-
Dørum, A.1
Tonstad, S.2
Liavaag, A.H.3
-
39
-
-
57649178821
-
Metabolic syndrome after risk-reducing salpingo-oophorectomy in women at high risk for hereditary breast ovarian cancer: A controlled observational study
-
Michelsen TM, Pripp AH, Tonstad S, et al: Metabolic syndrome after risk-reducing salpingo-oophorectomy in women at high risk for hereditary breast ovarian cancer: A controlled observational study. Eur J Cancer 45:82-89, 2009.
-
(2009)
Eur J Cancer
, vol.45
, pp. 82-89
-
-
Michelsen, T.M.1
Pripp, A.H.2
Tonstad, S.3
-
40
-
-
0003964363
-
-
Available at Accessed July 16, 2010
-
American Cancer Society: Cancer facts & figures 2010. Available at http://www.cancer.org/acs/groups/content/@nho/ documents/document/acspc-024113. pdf. Accessed July 16, 2010.
-
Cancer Facts & Figures 2010
-
-
-
41
-
-
20544434406
-
The metabolic syndrome and disturbances in hormone levels in long-term survivors of disseminated testicular cancer
-
DOI 10.1200/JCO.2005.02.176
-
Nuver J, Smit AJ, Wolffenbuttel BH, et al: The metabolic syndrome and disturbances in hormone levels in long-term survivors of disseminated testicular cancer. J Clin Oncol 23:3718-3725, 2005. (Pubitemid 46252467)
-
(2005)
Journal of Clinical Oncology
, vol.23
, Issue.16
, pp. 3718-3725
-
-
Nuver, J.1
Smit, A.J.2
Wolffenbuttel, B.H.R.3
Sluiter, W.J.4
Hoekstra, H.J.5
Sleijfer, D.T.6
Gietema, J.A.7
-
42
-
-
0037504532
-
Cardiovascular disease as a long-term complication of treatment for testicular cancer
-
DOI 10.1200/JCO.2003.04.173
-
Huddart RA, Norman A, Shahidi M, et al: Cardiovascular disease as a long-term complication of treatment for testicular cancer. J Clin Oncol 21:1513-1523, 2003. (Pubitemid 46594104)
-
(2003)
Journal of Clinical Oncology
, vol.21
, Issue.8
, pp. 1513-1523
-
-
Huddart, R.A.1
Norman, A.2
Shahidi, M.3
Horwich, A.4
Coward, D.5
Nicholls, J.6
Dearnaley, D.P.7
-
43
-
-
24644519960
-
Blood pressure and body mass index in long-term survivors of testicular cancer
-
Sagstuen H, Aass N, Fossa SD, et al: Blood pressure and body mass index in long-term survivors of testicular cancer. J Clin Oncol 23:4980-4990, 2005.
-
(2005)
J Clin Oncol
, vol.23
, pp. 4980-4990
-
-
Sagstuen, H.1
Aass, N.2
Fossa, S.D.3
-
44
-
-
17644431109
-
Cardiovascular morbidity in long-term survivors of metastatic testicular cancer
-
Meinardi MT, Gietema JA, van der Graaf WT, et al: Cardiovascular morbidity in long-term survivors of metastatic testicular cancer. J Clin Oncol 18:1725-1732, 2000.
-
(2000)
J Clin Oncol
, vol.18
, pp. 1725-1732
-
-
Meinardi, M.T.1
Gietema, J.A.2
Van Der Graaf, W.T.3
-
45
-
-
52249116769
-
Predicted cardiovascular mortality and reported cardiovascular morbidity in testicular cancer survivors
-
Haugnes HS, Aass N, Fossa SD, et al: Predicted cardiovascular mortality and reported cardiovascular morbidity in testicular cancer survivors. J Cancer Surviv 2:128-137, 2008.
-
(2008)
J Cancer Surviv
, vol.2
, pp. 128-137
-
-
Haugnes, H.S.1
Aass, N.2
Fossa, S.D.3
-
46
-
-
33644835617
-
Long-term risk of cardiovascular disease in 5-year survivors of testicular cancer
-
van den Belt-Dusebout AW, Nuver J, de Wit R, et al: Long-term risk of cardiovascular disease in 5-year survivors of testicular cancer. J Clin Oncol 24:467-475, 2006.
-
(2006)
J Clin Oncol
, vol.24
, pp. 467-475
-
-
Van Den Belt-Dusebout, A.W.1
Nuver, J.2
De Wit, R.3
-
47
-
-
0027082709
-
Hypercholesterolemia after chemotherapy for testis cancer
-
Raghavan D, Cox K, Childs A, et al: Hypercholesterolemia after chemotherapy for testis cancer. J Clin Oncol 10:1386-1389, 1992.
-
(1992)
J Clin Oncol
, vol.10
, pp. 1386-1389
-
-
Raghavan, D.1
Cox, K.2
Childs, A.3
-
48
-
-
0037434420
-
Excessive annual BMI increase after chemotherapy among young survivors of testicular cancer
-
DOI 10.1038/sj.bjc.6600714
-
Nord C, Fossa SD, Egeland T: Excessive annual BMI increase after chemotherapy among young survivors of testicular cancer. Br J Cancer 88:36-41, 2003. (Pubitemid 36241215)
-
(2003)
British Journal of Cancer
, vol.88
, Issue.1
, pp. 36-41
-
-
Nord, C.1
Fossa, S.D.2
Egeland, T.3
-
49
-
-
33847330070
-
Components of the metabolic syndrome in long-term survivors of testicular cancer
-
DOI 10.1093/annonc/mdl372
-
Haugnes HS, Aass N, Fossa SD, et al: Components of the metabolic syndrome in long-term survivors of testicular cancer. Ann Oncol 18:241-248, 2007. (Pubitemid 46323088)
-
(2007)
Annals of Oncology
, vol.18
, Issue.2
, pp. 241-248
-
-
Haugnes, H.S.1
Aass, N.2
Fossa, S.D.3
Dahl, O.4
Klepp, O.5
Wist, E.A.6
Svartberg, J.7
Wilsgaard, T.8
Bremnes, R.M.9
-
50
-
-
33746637660
-
Current development of mTOR inhibitors as anticancer agents
-
Faivre S, Kroemer G, Raymond E: Current development of mTOR inhibitors as anticancer agents. Nat Rev Drug Discov 5:671-688, 2006.
-
(2006)
Nat Rev Drug Discov
, vol.5
, pp. 671-688
-
-
Faivre, S.1
Kroemer, G.2
Raymond, E.3
-
51
-
-
77951282223
-
Emergent toxicities associated with the use of mTOR inhibitors in patients with advanced renal carcinoma
-
Rodriguez-Pascual J, Cheng E, Maroto P, Duran I: Emergent toxicities associated with the use of mTOR inhibitors in patients with advanced renal carcinoma. Anticancer Drugs 21:478-486, 2010.
-
(2010)
Anticancer Drugs
, vol.21
, pp. 478-486
-
-
Rodriguez-Pascual, J.1
Cheng, E.2
Maroto, P.3
Duran, I.4
-
52
-
-
77951729433
-
FDA approval summary: Temsirolimus as treatment for advanced renal cell carcinoma
-
Kwitkowski VE, Prowell TM, Ibrahim A,: FDA approval summary: Temsirolimus as treatment for advanced renal cell carcinoma. Oncologist 15:428-435, 2010.
-
(2010)
Oncologist
, vol.15
, pp. 428-435
-
-
Kwitkowski, V.E.1
Prowell, T.M.2
Ibrahim, A.3
-
53
-
-
48749128305
-
Temsirolimus safety profile and management of toxic effects in patients with advanced renal cell carcinoma and poor prognostic features
-
Bellmunt J, Szczylik C, Feingold J, et al: Temsirolimus safety profile and management of toxic effects in patients with advanced renal cell carcinoma and poor prognostic features. Ann Oncol 19:1387-1392, 2008.
-
(2008)
Ann Oncol
, vol.19
, pp. 1387-1392
-
-
Bellmunt, J.1
Szczylik, C.2
Feingold, J.3
-
54
-
-
48649107474
-
Efficacy of everolimus in advanced renal cell carcinoma: A double-blind, randomised, placebo-controlled phase III trial
-
Motzer RJ, Escudier B, Oudard S, et al: Efficacy of everolimus in advanced renal cell carcinoma: A double-blind, randomised, placebo-controlled phase III trial. Lancet 372:449-456, 2008.
-
(2008)
Lancet
, vol.372
, pp. 449-456
-
-
Motzer, R.J.1
Escudier, B.2
Oudard, S.3
-
55
-
-
33644847440
-
Safety, pharmacokinetic, and antitumor activity of SU11248, a novel oral multitarget tyrosine kinase inhibitor, in patients with cancer
-
Faivre S, Delbaldo C, Vera K, et al: Safety, pharmacokinetic, and antitumor activity of SU11248, a novel oral multitarget tyrosine kinase inhibitor, in patients with cancer. J Clin Oncol 24:25-35, 2006.
-
(2006)
J Clin Oncol
, vol.24
, pp. 25-35
-
-
Faivre, S.1
Delbaldo, C.2
Vera, K.3
-
56
-
-
23044510046
-
Safety and pharmacokinetics of the dual action Raf kinase and vascular endothelial growth factor receptor inhibitor, BAY 43-9006, in patients with advanced, refractory solid tumors
-
Clark JW, Eder JP, Ryan D, et al: Safety and pharmacokinetics of the dual action Raf kinase and vascular endothelial growth factor receptor inhibitor, BAY 43-9006, in patients with advanced, refractory solid tumors. Clin Cancer Res 11:5472-5480, 2005.
-
(2005)
Clin Cancer Res
, vol.11
, pp. 5472-5480
-
-
Clark, J.W.1
Eder, J.P.2
Ryan, D.3
-
57
-
-
74549205409
-
Management of sorafenib, sunitinib, and temsirolimus toxicity in metastatic renal cell carcinoma
-
Guevremont C, Alasker A, Karakiewicz PI: Management of sorafenib, sunitinib, and temsirolimus toxicity in metastatic renal cell carcinoma. Curr Opin Support Palliat Care 3:170-179, 2009.
-
(2009)
Curr Opin Support Palliat Care
, vol.3
, pp. 170-179
-
-
Guevremont, C.1
Alasker, A.2
Karakiewicz, P.I.3
-
58
-
-
0037208589
-
Phase II, randomized trial comparing bevacizumab plus fluorouracil (FU)/leucovorin (LV) with FU/LV alone in patients with metastatic colorectal cancer
-
Kabbinavar F, Hurwitz HI, Fehrenbacher L, et al: Phase II, randomized trial comparing bevacizumab plus fluorouracil (FU)/leucovorin (LV) with FU/LV alone in patients with metastatic colorectal cancer. J Clin Oncol 21:60-65, 2003.
-
(2003)
J Clin Oncol
, vol.21
, pp. 60-65
-
-
Kabbinavar, F.1
Hurwitz, H.I.2
Fehrenbacher, L.3
-
59
-
-
34248339065
-
Short- vs long-term androgen suppression plus external beam radiation therapy and survival in men of advanced age with node-negative high-risk adenocarcinoma of the prostate
-
DAmico AV, Denham JW, Bolla M, et al: Short- vs long-term androgen suppression plus external beam radiation therapy and survival in men of advanced age with node-negative high-risk adenocarcinoma of the prostate. Cancer 109:2004-2010, 2007.
-
(2007)
Cancer
, vol.109
, pp. 2004-2010
-
-
DAmico, A.V.1
Denham, J.W.2
Bolla, M.3
|